-- Robert Preidt
WEDNESDAY, Sept. 11 (HealthDay News) -- Researchers say they've
identified a genetic indicator of the long-term risk of breast
They compared three gene signature methods of predicting the
risk of recurrence in patients treated for estrogen-receptor
(ER)-positive breast cancer. They found that only the breast cancer
index (BCI) -- a "biomarker" based on the expression levels of
seven tumor-specific genes -- accurately identifies patients who
continues to be at risk for breast cancer recurrence after five
years of treatment with either tamoxifen or anastrozole, a drug in
the aromatase inhibitor class.
The other two methods examined in the study were the Oncotype Dx
Recurrence Score, the current gold standard for guiding clinical
decision making, and the ICH4 gene signature, which is used less
All three methods were able to predict recurrence risk in the
first five years, but only the breast cancer index was able to
accurately assess long-term recurrence risk, the study found. The
breast cancer index was able to clearly distinguish 60 percent of
patients whose risk was quite low from 40 percent who continued to
be at significant long-term risk, the researchers said.
The study was published online Sept. 12 in the journal
"We have validated a unique 'fingerprint' in the primary tumor of breast cancer patients that can help identify a high or low risk of cancer recurrence," study co-author Dr. Paul Goss, director of the breast cancer research program at Massachusetts General Hospital Cancer Center, said in a hospital news release. "This should enable us to offer prolonged treatment to patients who remain at risk and, importantly, to avoid the costs and side effects of treatment in those at low risk."
More than half the instances of recurrence in ER-positive breast
cancer occur after five years of therapy with tamoxifen or
anastrozole, so these findings are highly relevant to clinical
management, study leader Dr. Dennis Sgroi, of the MGH Cancer
Center, said in the news release.
"Since the BCI identifies two distinct risk groups, it may provide a much-needed tool in determining those patients who need extended hormonal therapy and those who may be spared its well-known adverse side effects," he explained.
The U.S. National Cancer Institute has more about
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.